ALLERGOLOGIE

ALLERGOLOGIE Journal

publication venue for

Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT) 2024
Treatment with dupilumab resulted in lower use of corticosteroids and antibiotics in patients with chronic rhinosinusitis with nasal polyps treated in real-world conditions in the United States 12 months 2024
Onset of Action, Maintenance and Persistence of Response to Dupilumab in chronic Rhinosinusitis with Nasal Polyps 2022
Onset of action, maintenance and persistence of response to dupilumab in chronic rhinosinusitis with nasal polyps 2022

International Standard Serial Number (ISSN)

0344-5062